Figures & data
Figure 1. Laboratory parameters before and during HU treatment of patient with Hb Volga (left panels) and Hb Köln (right panels). Start of HU therapy is indicated by an arrow in the top panels. Period of cholelithiasis (1), pneumonia (2), and Parvo B19 induced aplastic crisis, requiring red blood cell transfusions (3), are indicated with numerals for the patient with Hb Volga. Percentages of Hb Köln are shown by a dashed line with open circles. Hb Volga was not detectable by IEF, but a heterozygous presence of the mutation was confirmed by sequencing.
![Figure 1. Laboratory parameters before and during HU treatment of patient with Hb Volga (left panels) and Hb Köln (right panels). Start of HU therapy is indicated by an arrow in the top panels. Period of cholelithiasis (1), pneumonia (2), and Parvo B19 induced aplastic crisis, requiring red blood cell transfusions (3), are indicated with numerals for the patient with Hb Volga. Percentages of Hb Köln are shown by a dashed line with open circles. Hb Volga was not detectable by IEF, but a heterozygous presence of the mutation was confirmed by sequencing.](/cms/asset/6ae2fe14-c912-48b6-99b8-eaf4cc4b7819/ihem_a_1232655_f0001_b.jpg)
Table 1. Laboratory parameter values for the patient with Hb Volga.
Table 2. Laboratory parameter values for the patient with Hb Köln.